Clinical trial
A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia
NCT00770510 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia
- Lead sponsor
- Eisai Co., Ltd.
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- September 30, 2008
- Completion date
- May 31, 2010
- Enrollment
- 192 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.
primary insomnia